Literature DB >> 7798859

Comparison of home glucose monitoring with the oral glucose tolerance test to detect gestational glucose intolerance.

K A Peterson1, A M Peterson, V Corbett, S Tongen, M Guzman, R Mazze.   

Abstract

BACKGROUND: Recent evidence suggests that infant morbidity is increased among women who have abnormal prenatal glucose screening tests but who do not have gestational diabetes mellitus (GDM). These women fall into a diagnostic gray zone and historically have not been treated.
METHODS: Forty-eight pregnant women with abnormal oral glucose challenge test results performed self-monitored blood glucose (SMBG) testing seven times per day for 1 week before undergoing a diagnostic 100-g oral glucose tolerance test (OGTT). At delivery, perinatal complications and birthweights were recorded. Results of SMBG tests for women with normal OGTTs were correlated with infant birthweights.
RESULTS: Thirteen infants (37%) were found to be large for gestational age (LGA). Significant correlation was found between increasing birthweight and increasing average fasting SMBG values (P < .001), increasing percentage of SMBG values above 120 mg/dL (6.7 mmol/L) (P < .01), and increasing average SMBG values (P < .016).
CONCLUSIONS: Maternal home glucose values at 28 weeks correlate with the risk of LGA infant births among women in the diagnostic gray zone. Women with average fasting SMBG values > 95 mg/dL (5.3 mmol/L) are at increased risk for giving birth to LGA infants and may be more likely to exhibit complications usually associated with GDM.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7798859

Source DB:  PubMed          Journal:  J Fam Pract        ISSN: 0094-3509            Impact factor:   0.493


  1 in total

1.  Development of a fasting blood glucose-based strategy to diagnose women with gestational diabetes mellitus at increased risk of adverse outcomes in a COVID-19 environment.

Authors:  Michael d'Emden; Donald McLeod; Jacobus Ungerer; Charles Appleton; David Kanowski
Journal:  PLoS One       Date:  2020-12-03       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.